Method and compositions for modulating neovascularization
Patent 4808402 Issued on February 28, 1989. Estimated Expiration Date: 
May 29, 2007. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
May 29, 2007. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesMethod for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same Angiotropins of leukocytes and inflamed tissue, process for their biotechnical preparation, and pharmaceutical compositions thereof Controlled release formulation CDNA and gene for human angiogenin (angiogenesis factor) and methods of expression Patent #: 4721672 InventorsAssigneeApplicationNo. 07/056554 filed on 05/29/1987US Classes:424/78.06, Skin burn or open wound treatment424/423, Surgical implant or material424/618, Silver424/85.1, LYMPHOKINE514/2, Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI514/21, Produced by or extracted from animal tissue514/8Glycoprotein (carbohydrate containing)ExaminersPrimary: Schofer, Joseph L.Assistant: Kulkosky, Peter F. International ClassesA61K 38/19 (20060101)A61L 17/00 (20060101) A61L 15/16 (20060101) A61L 15/32 (20060101) A61L 26/00 (20060101) AbstractTumor necrosis factors possess the unexpected ability to induce angiogenesis, or neovascularization. Novel methods and TNF-containing compositions and articles are provided for the induction of neovascularization and rapid wound healing.Other References
Field of SearchSurgical implant or material | |
